Short-term biological variation of plasma uracil in a Caucasian healthy population.
5-fluorouracil
biological variation
dihydropyrimidine dehydrogenase (DPD) deficiency
uracil
Journal
Clinical chemistry and laboratory medicine
ISSN: 1437-4331
Titre abrégé: Clin Chem Lab Med
Pays: Germany
ID NLM: 9806306
Informations de publication
Date de publication:
26 07 2023
26 07 2023
Historique:
received:
16
11
2022
accepted:
22
02
2023
medline:
3
7
2023
pubmed:
2
3
2023
entrez:
1
3
2023
Statut:
epublish
Résumé
Plasma uracil is a new biomarker to assess the activity of dihydropyrimidine dehydrogenase before cancer treatment with fluoropyrimidine drugs. Knowledge on the biological variation of plasma uracil is important to assess the applicability of plasma uracil as a biomarker of drug tolerance and efficacy. A total of 33 apparently healthy individuals were submitted to sequential blood draws for three days. On the second day, blood draws were performed every third hour for 12 h. Plasma uracil was quantified by LC-MS/MS. The within-subject (CV The overall median value of plasma uracil was 10.6 ng/mL (range 5.6-23.1 ng/mL). The CV Plasma uracil is subject to tight homeostatic regulation without semidiurnal and day-to-day variation, however between-subject variation exists. This emphasizes plasma uracil as a well-suited biomarker for evaluation of dihydropyrimidine dehydrogenase activity, but four samples are required to establish the homeostatic set-point in a patient.
Identifiants
pubmed: 36856054
pii: cclm-2022-1167
doi: 10.1515/cclm-2022-1167
doi:
Substances chimiques
Uracil
56HH86ZVCT
Fluorouracil
U3P01618RT
Dihydrouracil Dehydrogenase (NADP)
EC 1.3.1.2
Biomarkers
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1490-1496Informations de copyright
© 2023 the author(s), published by De Gruyter, Berlin/Boston.
Références
Leichman, CG, Fleming, TR, Muggia, FM, Tangen, CM, Ardalan, B, Doroshow, JH, et al.. Phase II study of fluorouracil and its modulation in advanced colorectal cancer: a southwest oncology group study. J Clin Oncol 1995;13:1303–11. https://doi.org/10.1200/jco.1995.13.6.1303 .
doi: 10.1200/jco.1995.13.6.1303
Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency (EMA) . Assessment report: fluorouracil and fluorouracil related substances (capecitabine, tegafur and flucytosine) containing medicinal products ; 2020. Available from: https://www.ema.europa.eu/en/documents/referral/fluorouracil-fluorouracil-related-substances-article-31-referral-assessment-report_en.pdf .
INCa and HAS . Screening for dihydropyrimidine dehydrogenase deficiency to decrease the risk of severe toxicities related to fluoropyrimidines (5-fluorouracil or capecitabine) ; 2018. Available from: www.has-sante.fr/jcms/c_2891090/en/screening-for-dihydropyrimidine-dehydrogenase-deficiency-to-decrease-the-risk-of-severe-toxicities-related-to-fluoropyrimidines-5-fluorouracil-or-capecitabine-inahta-brief .
European Medicines Agency (EMA) . EMA recommendations on DPD testing prior to treatment with fluorouracil, capecitabine, tegafur and flucytosine ; 2020. Available from: https://www.ema.europa.eu/en/documents/referral/fluorouracil-fluorouracil-related-substances-article-31-referral-ema-recommendations-dpd-testing_en.pdf .
Meulendijks, D, Jacobs, BA, Aliev, A, Pluim, D, van Werkhoven, E, Deenen, MJ, et al.. Increased risk of severe fluoropyrimidine-associated toxicity in patients carrying a G to C substitution in the first 28-bp tandem repeat of the thymidylate synthase 2R allele. Int J Cancer 2016;138:245–53. https://doi.org/10.1002/ijc.29694 .
doi: 10.1002/ijc.29694
Fleming, RA, Milano, G, Thyss, A, Etienne, MC, Renée, N, Schneider, M, et al.. Correlation between dihydropyrimidine dehydrogenase activity in peripheral mononuclear cells and systemic clearance of fluorouracil in cancer patients. Cancer Res 1992;52:2899–902.
Milano, G, Etienne, MC, Pierrefite, V, Barberi-Heyob, M, Deporte-Fety, R, Renée, N. Dihydropyrimidine dehydrogenase deficiency and fluorouracil-related toxicity. Br J Cancer 1999;79:627–30. https://doi.org/10.1038/sj.bjc.6690098 .
doi: 10.1038/sj.bjc.6690098
Zhou, ZW, Wang, GQ, Wan, DS, Lu, ZH, Chen, YB, Li, S, et al.. The dihydrouracil/uracil ratios in plasma and toxicities of 5-fluorouracil-based adjuvant chemotherapy in colorectal cancer patients. Chemotherapy 2007;53:127–31. https://doi.org/10.1159/000099984 .
doi: 10.1159/000099984
Gamelin, E, Boisdron-Celle, M, Guérin-Meyer, V, Delva, R, Lortholary, A, Genevieve, F, et al.. Correlation between uracil and dihydrouracil plasma ratio, fluorouracil (5-FU) pharmacokinetic parameters, and tolerance in patients with advanced colorectal cancer: a potential interest for predicting 5-FU toxicity and determining optimal 5-FU dosage. J Clin Oncol 1999;17:1105. https://doi.org/10.1200/jco.1999.17.4.1105 .
doi: 10.1200/jco.1999.17.4.1105
Jiang, H, Lu, J, Ji, J. Circadian rhythm of dihydrouracil/uracil ratios in biological fluids: a potential biomarker for dihydropyrimidine dehydrogenase levels. Br J Pharmacol 2004;141:616–23. https://doi.org/10.1038/sj.bjp.0705651 .
doi: 10.1038/sj.bjp.0705651
Jacobs, BA, Deenen, MJ, Pluim, D, van Hasselt, JG, Krähenbühl, MD, van Geel, RM, et al.. Pronounced between-subject and circadian variability in thymidylate synthase and dihydropyrimidine dehydrogenase enzyme activity in human volunteers. Br J Clin Pharmacol 2016;82:706–16. https://doi.org/10.1111/bcp.13007 .
doi: 10.1111/bcp.13007
Madsen, AT, Hojbjerg, JA, Sorensen, BS, Winther-Larsen, A. Day-to-day and within-day biological variation of cell-free DNA. EBioMedicine 2019;49:284–90. https://doi.org/10.1016/j.ebiom.2019.10.008 .
doi: 10.1016/j.ebiom.2019.10.008
Aarsand, AK, Røraas, T, Fernandez-Calle, P, Ricos, C, Díaz-Garzón, J, Jonker, N, et al.. The biological variation data critical appraisal checklist: a standard for evaluating studies on biological variation. Clin Chem 2018;64:501–14. https://doi.org/10.1373/clinchem.2017.281808 .
doi: 10.1373/clinchem.2017.281808
Bartlett, WA, Braga, F, Carobene, A, Coşkun, A, Prusa, R, Fernandez-Calle, P, et al.. A checklist for critical appraisal of studies of biological variation. Clin Chem Lab Med 2015;53:879–85. https://doi.org/10.1515/cclm-2014-1127 .
doi: 10.1515/cclm-2014-1127
Braga, F, Panteghini, M. Generation of data on within-subject biological variation in laboratory medicine: an update. Crit Rev Clin Lab Sci 2016;53:313–25. https://doi.org/10.3109/10408363.2016.1150252 .
doi: 10.3109/10408363.2016.1150252
Fraser, CG, Harris, EK. Generation and application of data on biological variation in clinical chemistry. Crit Rev Clin Lab Sci 1989;27:409–37. https://doi.org/10.3109/10408368909106595 .
doi: 10.3109/10408368909106595
Røraas, T, Støve, B, Petersen, PH, Sandberg, S. Biological variation: evaluation of methods for constructing confidence intervals for estimates of within-person biological variation for different distributions of the within-person effect. Clin Chim Acta 2017;468:166–73. https://doi.org/10.1016/j.cca.2017.02.021 .
doi: 10.1016/j.cca.2017.02.021
Henricks, LM, Jacobs, BAW, Meulendijks, D, Pluim, D, van den Broek, D, de Vries, N, et al.. Food-effect study on uracil and dihydrouracil plasma levels as marker for dihydropyrimidine dehydrogenase activity in human volunteers. Br J Clin Pharmacol 2018;84:2761–9. https://doi.org/10.1111/bcp.13719 .
doi: 10.1111/bcp.13719
Capiau, S, Van Landschoot, A, Reyns, T, Stepman, H, de With, M, Knikman, J, et al.. Pre-analytical considerations for the analysis of uracil and 5,6-dihydrouracil in heparin plasma dihydropyrimidine dehydrogenase phenotyping using pretreatment uracil: a note of caution based on a large prospective clinical study. Clin Chem Lab Med 2022;60:e112–e5.
de With, M, Knikman, J, de Man, FM, Lunenburg, C, Henricks, LM, van Kuilenburg, ABP, et al.. Dihydropyrimidine dehydrogenase phenotyping using pretreatment uracil: a note of caution based on a large prospective clinical study. Clin Pharmacol Ther 2022;112:62–8. https://doi.org/10.1002/cpt.2608 .
doi: 10.1002/cpt.2608
Remaud, G, Boisdron-Celle, M, Hameline, C, Morel, A, Gamelin, E. An accurate dihydrouracil/uracil determination using improved high performance liquid chromatography method for preventing fluoropyrimidines-related toxicity in clinical practice. J Chromatogr B Anal Technol Biomed Life Sci 2005;823:98–107. https://doi.org/10.1016/j.jchromb.2005.05.044 .
doi: 10.1016/j.jchromb.2005.05.044
Paulsen, NH, Qvortrup, C, Vojdeman, FJ, Plomgaard, P, Andersen, SE, Ramlov, A, et al.. Dihydropyrimidine dehydrogenase (DPD) genotype and phenotype among Danish cancer patients: prevalence and correlation between DPYD-genotype variants and P-uracil concentrations. Acta Oncol 2022;61:1400–5. https://doi.org/10.1080/0284186X.2022.2132117 .
doi: 10.1080/0284186X.2022.2132117
Chavani, O, Jensen, BP, Strother, RM, Florkowski, CM, George, PM. Development, validation and application of a novel liquid chromatography tandem mass spectrometry assay measuring uracil, 5,6-dihydrouracil, 5-fluorouracil, 5,6-dihydro-5-fluorouracil, α-fluoro-β-ureidopropionic acid and α-fluoro-β-alanine in human plasma. J Pharm Biomed Anal 2017;142:125–35. https://doi.org/10.1016/j.jpba.2017.04.055 .
doi: 10.1016/j.jpba.2017.04.055